11920203

Source:http://linkedlifedata.com/resource/pubmed/id/11920203

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0019829, umls-concept:C0087111, umls-concept:C0205179, umls-concept:C0879265, umls-concept:C1442989
pubmed:issue	4
pubmed:dateCreated	2002-3-28
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100965523
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin, http://linkedlifedata.com/resource/pubmed/chemical/Chlorambucil, http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Etoposide, http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating..., http://linkedlifedata.com/resource/pubmed/chemical/Mechlorethamine, http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone, http://linkedlifedata.com/resource/pubmed/chemical/Prednisone, http://linkedlifedata.com/resource/pubmed/chemical/Procarbazine, http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
pubmed:status	MEDLINE
pubmed:issn	1466-4860
pubmed:author	pubmed-author:CardePP, pubmed-author:CavalliFF, pubmed-author:DiehlVV, pubmed-author:FranklinJJ
pubmed:issnType	Print
pubmed:volume	1
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	282-90
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:11920203-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11920203-Bleomycin, pubmed-meshheading:11920203-Chlorambucil, pubmed-meshheading:11920203-Clinical Trials, Phase III as Topic, pubmed-meshheading:11920203-Cyclophosphamide, pubmed-meshheading:11920203-Dacarbazine, pubmed-meshheading:11920203-Disease Progression, pubmed-meshheading:11920203-Disease-Free Survival, pubmed-meshheading:11920203-Dose-Response Relationship, Drug, pubmed-meshheading:11920203-Doxorubicin, pubmed-meshheading:11920203-Etoposide, pubmed-meshheading:11920203-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:11920203-Hematologic Diseases, pubmed-meshheading:11920203-Hodgkin Disease, pubmed-meshheading:11920203-Humans, pubmed-meshheading:11920203-Infertility, pubmed-meshheading:11920203-Mechlorethamine, pubmed-meshheading:11920203-Prednisolone, pubmed-meshheading:11920203-Prednisone, pubmed-meshheading:11920203-Procarbazine, pubmed-meshheading:11920203-Randomized Controlled Trials as Topic, pubmed-meshheading:11920203-Remission Induction, pubmed-meshheading:11920203-Retrospective Studies, pubmed-meshheading:11920203-Safety, pubmed-meshheading:11920203-Treatment Outcome, pubmed-meshheading:11920203-Vinblastine, pubmed-meshheading:11920203-Vincristine
pubmed:year	2000
pubmed:articleTitle	Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?
pubmed:affiliation	Institute Gustav-Roussy, Villejuif, France. carde@igr.fr
pubmed:publicationType	Journal Article, Review